Current Report · Items 8.01, 9.01 · 8-K

Inhibikase Therapeutics, Inc.

IKTNASDAQEQUITYCurrent

Other Events

Item 8.01. Other Events. On July 14, 2026, Inhibikase Therapeutics, Inc. (the “Company”) issued a press release relating to sales made by the Company under its at-the-market facility. The Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Filed Jul 14, 2026Accepted Jul 14, 2026, 8:11 AM EDTCIK 1750149Accession 0001193125-26-302580

View company →Permanent SEC source ↗

Press release in this filing

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility →

Company context

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit,” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients.

Current securities

IKTNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

INHIBIKASE THERAPEUTICS, INC. · 8-K · Filed 2026-07-14

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.001 par value

Symbol: IKT
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: duration_2026-07-14_to_2026-07-14

Dimensions: Not supplied

Accession 000119312526302580 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events

Filed exhibits (1)

EX-99.1 (by filename) d157026dex991.htm

EX-99.1 2 d157026dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility WILMINGTON, Del., July 14, 2026 - Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that it has sold 25,000,000 shares of the Company’s common stock to RA Capital Management through its at-the-market (“ATM”) facility for gross proceeds of $50 million. The Company expects that the additional capital raised through this financing, together with existing cash reserves, will support operations through topline data readout in Part B of the Company’s ongoing global Phase 3 IMPROVE-PAH clinical study, subject to the full exercise of the outstanding Series A and B Warrants. The shares of common stock described above were sold by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-288213), which was declared effective by the SEC on June 27, 2025, and a prospectus supplement relating to the ATM offering filed with the SEC pursuant to Rule 424(b) under th…

Open exhibit ↗

Get the free weekly BCS email.